
- Soligenix Inc (NASDAQ:SNGX) announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs).
- The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants.
- The NHPs had been double vaccinated with an adenovirus vaccine for COVID-19 seven months previously.
- Before administering the booster vaccine, neutralizing antibody levels against the original and Delta strains were low but detectable and undetectable for the omicron strain.
- Within one week of receiving the booster, neutralizing antibody levels increased 27-fold against the original and Delta strains. By three weeks, this increased up to 243-fold.
- Protective neutralizing antibody levels were also rapidly raised against omicron by one-week post-vaccination.
- Price Action: SNGX shares are up 0.99% at $0.69 during the market session on the last check Thursday.